CCL19 and myeloid sarcoma: TM rates of total B cells activated by anti-CD40/IgM and tested against a chemokine mix (CCL19, CCL20, CCL21, CXCL12, CXCL13) were overall heightened but also did not differ between patient-derived and donor-derived B cells (HC 1.23 ± 0.22%; MS, relapse: 1.15 ± 0.36%; MS, remission: 1.25 ± 0.39%; non-significant with p > 0.05 each) (Figure 4A).